NL301049I2 - crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout Download PDF

Info

Publication number
NL301049I2
NL301049I2 NL301049C NL301049C NL301049I2 NL 301049 I2 NL301049 I2 NL 301049I2 NL 301049 C NL301049 C NL 301049C NL 301049 C NL301049 C NL 301049C NL 301049 I2 NL301049 I2 NL 301049I2
Authority
NL
Netherlands
Prior art keywords
crisaborole
optionally
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
NL301049C
Other languages
English (en)
Dutch (nl)
Other versions
NL301049I1 (nl
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of NL301049I1 publication Critical patent/NL301049I1/nl
Publication of NL301049I2 publication Critical patent/NL301049I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL301049C 2005-02-16 2020-06-24 crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301049I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16
EP06735282.3A EP1853251B1 (en) 2005-02-16 2006-02-16 Halogen-substituted boronophthalides for the treatment of infections

Publications (2)

Publication Number Publication Date
NL301049I1 NL301049I1 (nl) 2020-07-01
NL301049I2 true NL301049I2 (nl) 2020-09-10

Family

ID=36917059

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301049C NL301049I2 (nl) 2005-02-16 2020-06-24 crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (26)

Country Link
US (11) US7582621B2 (enExample)
EP (4) EP2987796B1 (enExample)
JP (6) JP5038912B2 (enExample)
KR (4) KR101426220B1 (enExample)
CN (2) CN101914109B (enExample)
AU (3) AU2006214247C1 (enExample)
BE (1) BE2020C531I2 (enExample)
BR (1) BRPI0608431B8 (enExample)
CA (1) CA2597982C (enExample)
CY (3) CY1120695T1 (enExample)
DK (3) DK2987796T3 (enExample)
ES (4) ES2872962T3 (enExample)
FR (1) FR20C1024I2 (enExample)
HU (4) HUE054365T2 (enExample)
IL (2) IL207156A (enExample)
LT (1) LTC2343304I2 (enExample)
LU (1) LUC00157I2 (enExample)
MX (1) MX369262B (enExample)
NL (1) NL301049I2 (enExample)
NZ (3) NZ560448A (enExample)
PL (4) PL3424932T3 (enExample)
PT (4) PT2987796T (enExample)
RU (3) RU2414906C2 (enExample)
SI (3) SI2987796T1 (enExample)
WO (1) WO2006089067A2 (enExample)
ZA (4) ZA200707408B (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
ES2872962T3 (es) * 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7767657B2 (en) * 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
RU2642628C2 (ru) * 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
WO2009111676A2 (en) * 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
AU2009233711B2 (en) * 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010011354A2 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
SG172040A1 (en) * 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
WO2010118155A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
AP4039A (en) * 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (en) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antihelminth agents
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
DK2613788T3 (en) 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9162999B2 (en) 2011-09-28 2015-10-20 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
CA2850263A1 (en) * 2011-10-07 2013-04-11 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103270A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
AR094666A1 (es) 2013-01-30 2015-08-19 Dow Agrosciences Llc Uso de benzoxaborolas como agentes antimicrobianos volátiles en carnes, plantas o partes de plantas
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
AP2015008638A0 (en) 2013-02-01 2015-08-31 Anacor Pharmaceuticals Inc Boron-containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
MX363386B (es) 2013-10-03 2019-03-20 Dow Pharmaceutical Sciences Formulaciones de efinaconazol estabilizadas.
KR102612453B1 (ko) 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
BR112016018483A2 (pt) 2014-02-17 2018-07-10 Syngenta Participations Ag benzoxaboróis ativos do ponto de vista microbicida
WO2015134500A1 (en) 2014-03-03 2015-09-11 Cook Medical Technologies Llc Mechanical dilator
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
KR20170007347A (ko) * 2014-05-12 2017-01-18 애그로프레쉬 인크. 병원체에 대항하는 휘발성 적용
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106459097A (zh) * 2014-07-01 2017-02-22 第三共株式会社 作为抗菌剂的三环苯并氧杂硼杂环戊烯类
EP3209319B1 (en) 2014-10-21 2021-07-14 Hexima Limited A method of treatment of fungal infections
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
CA2981773C (en) 2015-04-09 2022-03-15 The Penn State Research Foundation Synergistic benzoxaborole-containing anti-fungicidal composition
MX2017012759A (es) 2015-04-09 2018-05-15 Anacor Pharmaceuticals Inc Moléculas pequeñas que contienen boro como agentes antiprotozoarios.
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
WO2017024022A1 (en) * 2015-08-06 2017-02-09 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
US10611780B2 (en) 2016-03-02 2020-04-07 Bill And Melinda Gates Foundation Boron-containing small molecules
CN109152932B (zh) * 2016-03-02 2021-09-28 比尔及梅琳达盖茨基金会 含硼小分子
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
WO2017155877A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Vaporized administration of pesticides
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
SG11201809984PA (en) 2016-05-09 2018-12-28 Anacor Pharmaceuticals Inc Crystal forms of crisaborole in free form and preparation method and use thereof
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
EP3484895A1 (en) 2016-07-12 2019-05-22 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (en) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Crisaborole production process
CA3054138A1 (en) * 2017-03-09 2018-09-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
US10981939B2 (en) 2017-05-12 2021-04-20 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole)
US10865217B2 (en) 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
ES2963960T3 (es) 2017-11-02 2024-04-03 Halcyon Labs Private Ltd Procedimiento nuevo para la preparación de Tavaborol y sus intermediarios
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
ES2949908T3 (es) 2018-01-09 2023-10-03 Halcyon Labs Private Ltd Proceso para la preparación de Crisaborol y sus intermedios
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
CN112384201A (zh) * 2018-07-31 2021-02-19 Mc2疗法有限公司 局部组合物
EP3836938A4 (en) 2018-08-18 2022-05-11 Boragen, Inc. SOLID FORMS OF SUBSTITUTED BENZOXAZOLE AND COMPOSITIONS THEREOF
KR102576125B1 (ko) 2018-10-05 2023-09-08 화이자 인코포레이티드 붕소 함유 pde4 억제제
CN113924084A (zh) 2019-03-20 2022-01-11 瑞塔·多布迈尔 药物组合物
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2021015841A1 (en) * 2019-07-25 2021-01-28 Massachusetts Institute Of Technology Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
WO2022043936A1 (en) 2020-08-31 2022-03-03 Pfizer Inc. Methods of protecting rna
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
JP2025520237A (ja) 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ， インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
CN117534695A (zh) * 2023-11-16 2024-02-09 南京农业大学 含二苯(硫)醚的苯并硼唑类化合物及其制备方法与应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6413751B1 (en) 1996-09-19 2002-07-02 The Board Of Trustees Of The Leland Stanford Jr. University DNA adenine methyltransferases and uses thereof
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
EP1127051A2 (en) 1998-11-06 2001-08-29 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
CN1370170A (zh) 1999-05-25 2002-09-18 宾夕法尼亚州研究基金会 Dna甲基转移酶抑制剂
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
EP1767629B1 (en) 1999-08-25 2011-04-20 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
EP1246630A4 (en) * 2000-01-06 2007-04-18 Marantech Holding Llc COMPOSITIONS AND METHODS FOR PROMOTING SKIN GROWTH AND TREATING SKIN STATE
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2002006316A2 (en) 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
ATE346074T1 (de) 2000-11-30 2006-12-15 Penn State Res Found Dna methyl transferase inhibitoren
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
DE60139510D1 (de) 2001-04-06 2009-09-17 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
US7217701B2 (en) 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
CN1325504C (zh) 2002-01-10 2007-07-11 宾夕法尼亚州研究基金会 制备二芳基硼酸烷基酯和络合的二芳基硼酸的方法
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
MXPA05006685A (es) 2002-12-18 2005-12-14 Anacor Pharmaceuticals Inc Antibioticos que contienen complejos de acido borinico y metodos de uso.
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
CN1829521B (zh) 2003-06-16 2011-01-26 安纳考尔医药公司 耐水解的含硼治疗剂和使用方法
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
EP1699792A1 (en) 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
CN1980694B (zh) 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
US20060251689A1 (en) 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
RU2642628C2 (ru) 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
BRPI0713010A2 (pt) 2006-06-12 2012-10-09 Anacor Pharmaceuticals Inc compostos para o tratamento de doença periodontal
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos

Also Published As

Publication number Publication date
JP2016020374A (ja) 2016-02-04
EP2343304A1 (en) 2011-07-13
PT2987796T (pt) 2018-10-18
JP2017105826A (ja) 2017-06-15
PL2987796T3 (pl) 2018-12-31
US20190048026A1 (en) 2019-02-14
KR20130100019A (ko) 2013-09-06
ES2872962T3 (es) 2021-11-03
SI2987796T1 (sl) 2018-11-30
US7582621B2 (en) 2009-09-01
US20210070780A1 (en) 2021-03-11
BRPI0608431B1 (pt) 2020-09-15
CN101160124A (zh) 2008-04-09
DK3424932T3 (da) 2021-05-25
RU2016145916A (ru) 2018-05-23
US20130244980A1 (en) 2013-09-19
US8889656B2 (en) 2014-11-18
RU2606947C2 (ru) 2017-01-10
US20110319361A1 (en) 2011-12-29
JP2008535781A (ja) 2008-09-04
HUS2000019I1 (hu) 2020-07-28
JP5038912B2 (ja) 2012-10-03
NL301049I1 (nl) 2020-07-01
EP2987796B1 (en) 2018-08-08
EP3424932A1 (en) 2019-01-09
IL185080A0 (en) 2008-08-07
BE2020C531I2 (enExample) 2025-09-05
KR20100105869A (ko) 2010-09-30
HUE026021T2 (en) 2016-05-30
KR20070112390A (ko) 2007-11-23
NZ598441A (en) 2013-07-26
EP1853251A2 (en) 2007-11-14
CN101914109A (zh) 2010-12-15
US20100190748A1 (en) 2010-07-29
RU2016145916A3 (enExample) 2020-07-21
FR20C1024I1 (enExample) 2020-07-31
CY2020027I2 (el) 2021-01-27
KR101337068B1 (ko) 2013-12-06
HK1221956A1 (en) 2017-06-16
EP3424932B1 (en) 2021-04-07
EP1853251A4 (en) 2010-01-13
AU2010203096C1 (en) 2012-09-20
SI2343304T1 (sl) 2015-08-31
NZ560448A (en) 2009-08-28
CA2597982C (en) 2014-07-08
ES2686981T3 (es) 2018-10-23
HK1109735A1 (en) 2008-06-20
FR20C1024I2 (fr) 2021-07-09
KR101337045B1 (ko) 2013-12-05
KR101456815B1 (ko) 2014-10-31
JP2014132031A (ja) 2014-07-17
US20060234981A1 (en) 2006-10-19
KR20130095330A (ko) 2013-08-27
RU2414906C2 (ru) 2011-03-27
EP1853251B1 (en) 2013-04-24
LTPA2020524I1 (lt) 2020-09-10
CA2597982A1 (en) 2006-08-24
LUC00157I2 (enExample) 2021-07-06
DK2987796T3 (en) 2018-09-17
LTC2343304I2 (lt) 2022-11-10
ZA201005380B (en) 2016-08-31
NZ578297A (en) 2010-11-26
ZA200707408B (en) 2009-11-25
AU2006214247C1 (en) 2012-11-08
KR101426220B1 (ko) 2014-08-05
BRPI0608431A2 (pt) 2009-12-29
JP6046876B2 (ja) 2016-12-21
PT3424932T (pt) 2021-05-19
ES2414095T3 (es) 2013-07-18
PT1853251E (pt) 2013-07-19
RU2007134429A (ru) 2009-03-27
US8039451B2 (en) 2011-10-18
PL2343304T3 (pl) 2015-09-30
CY1124503T1 (el) 2022-07-22
CY1120695T1 (el) 2019-12-11
HUE040060T2 (hu) 2019-02-28
WO2006089067A3 (en) 2007-07-19
PL1853251T3 (pl) 2013-09-30
CN101914109B (zh) 2014-07-23
US20160108063A1 (en) 2016-04-21
ZA201506944B (en) 2018-08-29
US20190330245A1 (en) 2019-10-31
SI3424932T1 (sl) 2021-08-31
DK2343304T3 (en) 2015-06-29
BRPI0608431B8 (pt) 2021-05-25
AU2011200994A1 (en) 2011-03-31
PL3424932T3 (pl) 2021-09-20
ES2540966T3 (es) 2015-07-15
ZA200905950B (en) 2010-11-24
EP2343304B1 (en) 2015-06-10
JP2013018778A (ja) 2013-01-31
LUC00157I1 (enExample) 2020-06-08
IL207156A (en) 2014-04-30
IL185080A (en) 2012-07-31
AU2010203096A1 (en) 2010-08-12
JP2010248265A (ja) 2010-11-04
HK1160139A1 (en) 2012-08-10
AU2006214247B2 (en) 2010-08-05
MX369262B (es) 2019-11-04
US20140142064A1 (en) 2014-05-22
US20150065459A1 (en) 2015-03-05
RU2010133524A (ru) 2012-02-20
US20170066788A1 (en) 2017-03-09
EP2987796A1 (en) 2016-02-24
AU2010203096B2 (en) 2010-12-02
AU2006214247A1 (en) 2006-08-24
WO2006089067A2 (en) 2006-08-24
CY2020027I1 (el) 2021-01-27
PT2343304E (pt) 2015-08-26
HUE054365T2 (hu) 2021-09-28
US8440642B2 (en) 2013-05-14

Similar Documents

Publication Publication Date Title
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl) Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301299I2 (nl) Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301021I2 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300946I2 (nl) Brexpiprazole, desgewenst in de vorm van een zout
NL301321I2 (nl) Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301256I2 (nl) cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301057I1 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL300909I2 (nl) Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300971I2 (nl) Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301033I2 (nl) Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL301209I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
FIC20253002I1 (fi) Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301041I2 (nl) Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan
NL300974I2 (nl) Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout